Surprisingly, RANK inhibition with the monoclonal antibody denosumab, which binds to RANKL and therefore blocks binding of RANKL to RANK, resulted in significantly prolonged survival, especially in patients with NSCLC adenocarcinomas and squamous tumors. Here, TNFRSF11A is linked to adenocarcinoma.